[ad_1]
Fintel reports that on April 21, 2023, Maxim Group maintained coverage of Augmedix (OTC:AUGX) with a Buy recommendation.
Analyst Price Forecast Suggests 67.21% Upside
As of April 6, 2023, the average one-year price target for Augmedix is $5.10. The forecasts range from a low of $4.04 to a high of $6.30. The average price target represents an increase of 67.21% from its latest reported closing price of $3.05.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Augmedix is $41MM, an increase of 32.41%. The projected annual non-GAAP EPS is -$0.58.
What is the Fund Sentiment?
There are 46 funds or institutions reporting positions in Augmedix. This is an increase of 6 owner(s) or 15.00% in the last quarter. Average portfolio weight of all funds dedicated to AUGX is 0.24%, a decrease of 15.27%.
What are Other Shareholders Doing?
Redmile Group holds 14,380K shares representing 38.32% ownership of the company. No change in the last quarter.
DCM International VI holds 4,169K shares representing 11.11% ownership of the company. In it’s prior filing, the firm reported owning 4,438K shares, representing a decrease of 6.46%. The firm decreased its portfolio allocation in AUGX by 11.16% over the last quarter.
Samjo Capital holds 1,700K shares representing 4.53% ownership of the company. In it’s prior filing, the firm reported owning 850K shares, representing an increase of 50.00%. The firm increased its portfolio allocation in AUGX by 85.63% over the last quarter.
Perkins Capital Management holds 1,680K shares representing 4.48% ownership of the company. In it’s prior filing, the firm reported owning 447K shares, representing an increase of 73.41%. The firm decreased its portfolio allocation in AUGX by 99.62% over the last quarter.
Millrace Asset Group holds 825K shares representing 2.20% ownership of the company. In it’s prior filing, the firm reported owning 825K shares, representing an increase of 0.07%. The firm decreased its portfolio allocation in AUGX by 99.90% over the last quarter.
See all Augmedix regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link
